Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Semin. Cancer Biol. 17, 330-343 (2007)
The clear evidence that tumor-infiltrating lymphocytes with anti-tumor activity exist in situ raises the question why renal cell carcinomas (RCCs) progress in vivo. A complex array of factors and pathways has been identified that impinges on innate and adaptive effector cells thereby inhibiting their activity against RCCs. The current picture of suppressive mechanisms that contribute to the failure of the immune system to control RCCs is reviewed here. Understanding these complex host-tumor interactions has broad implications for successful application of cytokine therapy and other forms of immunotherapy for RCC.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
7.378
2.108
33
34
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Renal cell carcinoma; Immune suppression; Tumor escape; Cytokine therapies; Immune therapies
Sprache
englisch
Veröffentlichungsjahr
2007
HGF-Berichtsjahr
2007
ISSN (print) / ISBN
1044-579X
e-ISSN
1096-3650
Zeitschrift
Seminars in Cancer Biology
Quellenangaben
Band: 17,
Heft: 4,
Seiten: 330-343
Verlag
Saunders
Verlagsort
Philadelphia, Pa.
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Molecular Immunology (IMI)
POF Topic(s)
30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
Forschungsfeld(er)
Immune Response and Infection
PSP-Element(e)
G-501700-001
WOS ID
000249375000008
Scopus ID
34547653931
PubMed ID
17656104
Erfassungsdatum
2007-06-23